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Brief communication
A 12-month follow-up study of treating
overweight schizophrenic patients with
aripiprazole
Introduction
The absolute risk of developing coronary heart
disease is around twice as high in schizophrenic
patients compared with the general population (1).
One of the reasons for this is the high (1.5–2-fold)
prevalence of overweight in this population (2).
Antipsychotic drugs can have a considerable
impact on weight. Of the second-generation anti-
psychotic drugs, clozapine and olanzapine cause
the largest weight gain followed by risperidone and
quetiapine. Less weight gain appears to be associ-
ated with aripiprazole and ziprasidone (3). Treat-
ment for overweight consists mostly of lifestyle
interventions. Another option is a switch to an
antipsychotic drug with lower weight gain capac-
ity, such as aripiprazole (4). After switching
patients to aripiprazole weight changes between
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Objective: To investigate the feasibility of switching overweight
schizophrenic patients to aripiprazole and to assess the impact of
12 months of aripiprazole treatment on weight in routine practice.
Method: This was a non-controlled cohort study in overweight
schizophrenic patients. Data were collected before treatment with
aripiprazole was started and at 12-month follow-up.
Results: A total of 53 patients were included; of these 55% continued
using aripiprazole for 12 months. Aripiprazole treatment for
12 months (P = 0.027) and stopping clozapine or olanzapine
treatment (P = 0.038) predicted weight loss (‡3 kg). Patients receiving
aripiprazole monotherapy (n = 16, mean )3.0 kg) had similar weight
loss than patients receiving aripiprazole in addition to another
antipsychotic drug (n = 13, mean )4.4 kg).
Conclusion: In routine practice once aripiprazole treatment was
started, more than half of the patients remained on aripiprazole and
most of them lost weight. Adding aripiprazole to clozapine gave similar
weight loss as monotherapy with aripiprazole.
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Significant outcomes
• Aripiprazole treatment over 12 months was a signiﬁcant predictor for weight loss.
• Adding aripiprazole to clozapine is an option for overweight patients on clozapine.
• Patients and psychiatrists are reluctant to change antipsychotic treatment for overweight patients.
Limitations
• Only 53 patients could be included in the study.
• There was no control group to compare treatment of aripiprazole.
• Other factors such as changes in lifestyle could also have an effect in patients treated with
aripiprazole, but were not included in the analysis.
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+0.04 kg after 52 weeks (5) and )5.5 kg after
12 weeks (6) were found. Six studies were con-
ducted over a relatively short period of time (4–
18 weeks) (6–11). Four studies followed patients
for 26 weeks or longer (5, 12–14). Three of the
studies with longer follow-up were randomized
controlled clinical trials (RCTs) or extension of
RCTs. Patients who received aripiprazole were
compared with patients on olanzapine (5, 13, 14),
quetiapine (14) or risperidone (14). Patients receiv-
ing aripiprazole gained less or lost weight (between
+0.04 and )1.4 kg) compared with patients in the
other treatment arm, who gained on average
weight in all three studies (between +1.4 and
+4.23 kg). However, these studies used strict
inclusion and exclusion criteria, such as excluding
patients on clozapine (13, 14), or including only a
small number of patients on clozapine (5, 15).
There was only one study conducted in routine
practice; patients lost on average 2.7 kg (12).
Unfortunately overweight was not an inclusion
criterion for this study and baseline antipsychotic
drugs were not recorded. Therefore, it remains
unknown whether the eﬀects of aripiprazole on
overweight patients shown in RCTs will also be
found in long-term treatment in routine practice.
Aims of the study
To investigate the feasibility of switching over-
weight schizophrenic patients to aripiprazole and
to assess the impact of 12 months aripiprazole
treatment on weight in routine practice.
Material and methods
This was a non-controlled cohort study. It was
carried out in a mental health care centre in the
North of the Netherlands, covering about 175 000
inhabitants. Between September 2004 and Febru-
ary 2006 patients were included if they had a
diagnosis of schizophrenia or other psychotic
disorder (DSM criteria 295-298), if their body
mass index (BMI) was >25 and ⁄or their waist
circumference was >88 cm for females and
>102 cm for males [threshold values for metabolic
syndrome NCEP ⁄ATP III (16)] and if patient and
psychiatrist agreed on starting treatment with
aripiprazole. All patients gave informed consent.
Aripiprazole was started additionally to baseline
antipsychotic drug and after 2–4 weeks the dose of
baseline antipsychotic drug was reduced stepwise
aiming at stopping the baseline antipsychotic drug.
Data were collected at baseline and at 12-month
follow-up assessment. A trained nurse assessed
patients somatic and mental health using a
standardized patient interview, including questions
about medication and psychiatric symptoms, and a
short physical examination, including waist cir-
cumference and blood pressure. At the same time,
laboratory values, including fasting glucose and
triglycerides, were measured. The patients psychi-
atrist discussed the ﬁndings with the patient and
decided on further treatment options, including
starting treatment with aripiprazole. Our study was
part of a disease management programme, which
aimed at evaluating standard of care, patients
needs and eﬀectiveness of interventions. Other
interventions oﬀered to overweight patients
included consultation by a dietician, exercise pro-
grammes and ⁄or referral to general practitioner for
further medical treatment.
Data were analysed to ﬁnd predictive variables
for weight loss (‡3 kg). In the logistic regression
model we included the variables aripiprazole use
for 12 months, age (>35 years), sex (male) and
stopping clozapine ⁄olanzapine, deﬁned as receiv-
ing clozapine ⁄olanzapine at baseline, but not at
12-month follow-up. Patients were excluded from
this analysis if data were missing for any of the
predictive variables.
Patient characteristics were compared between
patients who discontinued and who continued
treatment with aripiprazole using the t-test,
Mann–Whitney test and chi-squared test. Weight
changes and changes in antipsychotic drug treat-
ment were analysed descriptively on a patient level
for patients who continued and discontinued using
aripiprazole. The number of patients losing or
gaining 7% or more of their baseline weight was
calculated for better comparison with other pub-
lished studies (5, 10, 13, 14). In a subanalysis
weight change was calculated for patients receiving
aripiprazole in addition to their baseline antipsy-
chotic drug. For patients receiving clozapine in
combination with aripiprazole, dosage at 12 month
assessment and change in dosage of clozapine were
calculated.
Results
During the inclusion period, in total, 405 patients
were screened in the disease management
programme and 298 (74%) of these patients were
overweight (BMI >25 and ⁄or waist circumference
>88 cm for females and >102 cm for males).
A total of 53 (21 female, 32 male) patients were
included in the study. In addition, 11 patients
received aripiprazole during the inclusion period of
the study but could not be included in the study
(nine patients did not have a baseline screening and
two patients were not overweight at baseline
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screening). At baseline patients were on average
35.0 years old with an average disease duration of
10 years (Table 1). Olanzapine (n = 18, 34%) and
clozapine (n = 15, 28%) were the most frequently
prescribed monotherapy of antipsychotic drugs.
The average weight of patients was 97 kg (range:
69–135 kg) and average BMI was 31. Of the 53
patients who started with aripiprazole, after
12 months, six patients (11%) were lost to
follow-up, 18 patients (34%) had discontinued
using aripiprazole and 29 patients (55%) had taken
aripiprazole during the entire study period. Of the
patients who continued using aripiprazole, 16
(55%) patients received aripiprazole as monother-
apy, nine (31%) patients in combination with
clozapine and four (14%) patients in combination
with another antipsychotic drug. Reasons for
discontinuation were ineﬀectiveness (n = 13),
side-eﬀects (n = 1), non-compliance (n = 2) or
patients request (n = 2).
There were 46 patients with complete data for
performing a logistic regression for identifying
variables predicting weight loss (‡3 kg) after
12 months (Table 2). Receiving aripiprazole for
12 months and stopping clozapine or olanzapine
were statistically signiﬁcant predictors for weight
loss. Ten patients stopped olanzapine and one
patient clozapine treatment between both assess-
ments. Table 1 shows the comparison of patients
who discontinued and who continued using
aripiprazole for 12 months; patients who discon-
tinued aripiprazole had signiﬁcant higher
weight (P = 0.024) and were more often male
(P = 0.028).
Patients who continued aripiprazole for
12 months lost on average 3.6 kg (between )27
and +10 kg); this was 4% of baseline weight.
Twelve (23%) patients lost 7% or more and three
(6%) patients gained 7% or more of baseline
weight. Weight changes for patients who discon-
tinued aripiprazole ranged between )5.6 and









(n = 18) P-values
Female 21 (40) 4 (67) 14 (48) 3 (17) P = 0.028
Male 32 (60) 2 (33) 15 (52) 15 (83)
Age in years 35 (SD=10.1) 33 (SD=9.4) 34 (SD=10.7) 38 (SD=9.3) P = 0.144§
Schizophrenia 35 (66) 3 (50) 19 (66) 13 (72) P = 0.837
Schizoaffective disorder 9 (17) 1 (17) 5 (17) 3 (17)
Other psychotic disorder 9 (17) 2 (33) 5 (17) 2 (11)
Duration of disease in years 10.4 (SD=8.9; n = 48) 10.7 (SD=9.4; n = 6) 10.9 (SD=9.8; n = 25) 9.6 (SD=7.8; n = 17) P = 0.888§
Olanzapine 18 (34) 1 (17) 9 (31) 8 (44) P = 0.141
Clozapine 15 (28) 0 9 (31) 6 (33)
Risperidone 10 (19) 1 (17) 8 (28) 1 (6)
Other antipsychotics 4 (8) 2 (33) 2 (7) 0
Combinations of antipsychotics 5 (9) 1 (17) 1 (3) 3 (17)
No antipsychotic 1 (2) 1 (17) 0 0
Antidepressants 22 (42) 3 (50) 13 (45) 6 (33) P = 0.435
Antimuscarinic drugs 4 (8) 0 2 (7) 2 (11) P = 0.615
Hypnotics 9 (17) 2 (33) 5 (17) 2 (11) P = 0.566
Anxiolytics 5 (9) 1 (17) 2 (7) 2 (11) P = 0.615
Mood stabilizer 8 (15) 1 (17) 2 (7) 5 (28) P = 0.051
Weight in kg 97 (SD = 15.1) 88 (SD = 12.3) 95 (SD = 14.3) 105 (SD = 14.7) P = 0.024–
BMI 31.0 (SD = 4.1) 31.6 (SD = 5.3) 30.6 (SD = 3.9) 31.5 (SD = 4.3) P = 0.444§
Waist circumference in cm 108 (SD = 12.0) 108 (SD = 13.0) 106 (SD = 12.1) 112 (SD = 11.3) P = 0.064§
Male 108 (SD = 10.0) 110 (SD = 3.5) 104 (SD = 9.3) 111 (SD = 10.3)
Female 109 (SD = 14.9) 107 (SD = 16.6) 107 (SD = 14.7) 115 (SD = 17.9)
Metabolic syndrome* 24 (45) 4 (67) 13 (45) 7 (39) P = 0.638§
Values within parenthesis are expressed in percentage, unless otherwise stated.
*Based on the definition of ATP ⁄ NCEP (16). For missing glucose values, HbA1c values were used (‡6.2%).
P-values comparing patients who continued and who discontinued using aripiprazole.
P-values calculated using the chi-squared test.
§P-values calculated using the Mann–Whitney test.
–P-values calculated using the t-test.






Age >35 years 0.660 0.13–3.37 0.617
Male sex 0.492 0.10–2.41 0.381
Aripiprazole treatment for 12 months 14.011 1.34–146 0.027
Stopping clozapine ⁄ olanzapine 6.969 1.12–43.6 0.038
Schorr et al.
248
+21.7 kg, average weight gain was 4 kg (4% of
baseline weight). No patient lost 7% or more while
four patients (22%) gained 7% or more of their
baseline weight.
Patients with aripiprazole monotherapy
(n = 16) lost on average 3.0 kg ()3.2% of baseline
weight) and patients with combination therapy
(n = 13) lost on average 4.4 kg ()4.4% of baseline
weight). Two of the patients on combination
therapy received a combination of olanzapine and
aripiprazole and nine a combination of clozapine
and aripiprazole. In these patients, average dosage
at 12 month follow-up was 19 mg (SD = 8.5)
aripiprazole and 328 mg (SD = 177.0) clozapine.
On average, baseline clozapine dosage was reduced
by 28% (between )92% and +50%).
Discussion
In our study it was feasible to switch 55% of the
patients successfully to aripiprazole mono- or
combination therapy. However, in relation to the
298 patients who fulﬁlled the inclusion criteria
(overweight and diagnosis) during the study
period, only in 21% (n = 64) aripiprazole treat-
ment was started. Eighteen per cent (n = 53) of
the patients were included in the study and 11%
(n = 29) were treated with aripiprazole over
12 months. This low percentage shows that switch-
ing patients to aripiprazole was not considered as
one of the main treatment options in overweight
patients. Probably the main reason for this low
percentage is the relatively high risk for relapse
when switching medication in chronic psychiatric
patients. Consequently, psychiatrists and patients
are hesitant to change antipsychotic medication,
especially in treatment-resistant patients receiving
clozapine, which was one-third of our population.
In our study the main reason for discontinuing
aripiprazole was worsening of psychiatric symp-
toms (n = 13, 72% of patients who discontinued).
Patients who eventually chose to receive aripip-
razole and continued treatment had a high chance
of losing weight. Patients who were treated for
12 months with aripiprazole lost on average
weight, while patients who discontinued using
aripiprazole gained on average weight. The average
weight loss for patients who were treated for
12 months with aripiprazole was 3.6 kg, which is
within the range of published literature values
[between )5.6 kg (6) and +0.04 kg (5)], and was
higher than in other published long-term studies
[between )2.7 kg (14) and +0.04 kg (5)]. However,
patients who were motivated to continue using
aripiprazole throughout the study may also have
been motivated to lose weight. Comparing charac-
teristics of patients who continued with those who
discontinued using aripiprazole, we found that
patients who discontinued were more often male
and had a higher baseline weight. The high
percentage of men in the discontinuation group
may be at least partly due to the lower compliance
rate seen in male schizophrenic patients (17). The
higher baseline weight of patients can be explained
by the signiﬁcantly higher number of male patients.
This would suggest that male patients may not
beneﬁt from aripiprazole treatment the same way
as female patients and may therefore stop aripip-
razole.
The other signiﬁcant predicting factor for weight
loss was stopping clozapine or olanzapine. There
was one patient who stopped clozapine, and 10
patients who stopped olanzapine. Patients who
received clozapine at baseline were more likely to
receive aripiprazole in addition to clozapine than to
stop clozapine treatment. Surprisingly we found
that patients receiving a combinationof aripiprazole
and clozapine showed similar weight loss as patients
receiving aripiprazole monotherapy. Similar to data
from Henderson et al. (7), our study would there-
fore suggest that adding aripiprazole is an option in
overweight patients on clozapine. This needs to be
further investigated in a larger number of patients
including a control group.
This study was limited by the low number of
patients included in the study. Therefore, only a
limited number of variables could be included in
the logistic regression. Many other factors includ-
ing lifestyle changes or changes in co-medication
could also have an eﬀect on weight.
In conclusion, in routine practice, only a small
percentage of the total number of overweight
psychiatric patients were switched to aripiprazole.
Once aripiprazole treatment was started, more
than half of the patients remained on aripiprazole
and most of them lost weight. Adding aripiprazole
to clozapine gave similar weight loss as monother-
apy with aripiprazole.
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